000 a
999 _c9632
_d9632
003 OSt
005 20191009094803.0
008 191009b xxu||||| |||| 00| 0 eng d
040 _aAIKTC-KRRC
_cAIKTC-KRRC
100 _99775
_aKirpekar, Vivek C.
245 _a276© 2019 Indian Journal of Pharmacology Published by Wolters Kluwer - MedknowLurasidone‑induced anemia: Is there a need for hematological monitoring?
250 _aVol.51(4), July-Aug
260 _aMumbai
_bWolter Kluwer
_c2019
300 _a266-278p.
520 _aLurasidone is a newer drug used for treating schizophrenia and depression in bipolar disorder. Although comparatively safe, some side effects can occur with its use such as akathisia, extrapyramidal reaction, metabolic syndrome, and hyperprolactinemia. Blood dyscrasia with lurasidone is rarely reported in the literature except for few case reports. We present two cases of schizophrenia, treated with lurasidone developing anemia after variable period of treatment and reverting after stopping lurasidone. These cases emphasize the timely monitoring of blood parameters for prevention or early detection of anemia in patients treated with lurasidone.
650 0 _94774
_aPHARMACOLOGY
700 _99777
_aFaye, Abhijeet D.
773 0 _x0253-7613
_tIndian Journal of Pharmacology
_dAndheri - Mumbai Wolters Kluwer India Private Limited
856 _uhttp://www.ijp-online.com/temp/IndianJPharmacol514276-864315_001424.pdf
_yClick here
942 _2ddc
_cAR